TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| S | %ret | 1 | 1 | 3 | -5 | -13 | -4 | -1 | -37 | -59 | -20 |
| S | %wins | 100 | 100 | 33 | 67 | 67 | 100 | 78 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
8/23/16 18:16 | 8/19/16 | OGXI | Oncogenex Pharmaceuticals, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Bencich John | WA | O | CFO | S.d | -1 | 0.5700 | 0 | -1 | -13 | 9 | D | -82 | -77 | -5 | -36 | -41 | -36 | -34 | 12 | 0 | -9 | -17 | -19 | 5 | |
3/16/16 18:29 | 3/15/16 | OGXI | Oncogenex Pharmaceuticals, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Bencich John | WA | O | CFO | S.d | -1 | 0.8300 | 0 | -1 | -12 | 6 | D | -93 | -64 | -67 | -29 | 34 | 32 | 11 | 6 | -4 | -6 | 1 | 31 | -36 | -38 |
8/20/15 13:03 | 8/18/15 | OGXI | Oncogenex Pharmaceuticals, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Bencich John | WA | O | CFO | S.d | -4 | 2.76 | 4 | -1 | -29 | 4 | D | -68 | -14 | 24 | 48 | 33 | -14 | -13 | -5 | -11 | -24 | 4 | -16 | -79 | -80 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |